Fate Therapeutics (FATE) Profit After Tax (2012 - 2026)
Fate Therapeutics (FATE) posted Profit After Tax of -$31.2 million for Q1 2026, up 3.7% on a QoQ basis from -$32.4 million in Q4 2025, and up 17.2% year-over-year from -$26.6 million in Q1 2025.
Fate Therapeutics (FATE) Profit After Tax (2012 - 2026) Analysis & Trends
Fate Therapeutics' Profit After Tax history runs 15 years deep, the most recent figure standing at -$31.2 million for Q1 2026.
- Quarterly Profit After Tax rose 17.2% year-over-year to -$31.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$129.9 million (up 26.04% YoY) and the FY2025 annual result came in at -$136.5 million, up 26.63% from the prior year.
- Profit After Tax was -$31.2 million for Q1 2026 at Fate Therapeutics, up from -$32.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$18.9 million in Q1 2023 and bottomed at -$83.6 million in Q3 2022.
- A 5-year average of -$46.8 million and a median of -$45.2 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax jumped 71.26% — and 2024, when it slumped 154.25%.
- Fate Therapeutics' Profit After Tax stood at -$55.0 million in 2022, then increased by 19.73% to -$44.1 million in 2023, then retreated by 17.63% to -$51.9 million in 2024, then jumped by 37.55% to -$32.4 million in 2025, then gained by 3.7% to -$31.2 million in 2026.
- Business Quant data shows FATE's Profit After Tax at -$31.2 million in Q1 2026, -$32.4 million in Q4 2025, and -$32.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | -31.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.21 Mn |
| Dec 31, 2025 | -32.41 Mn |
| Sep 30, 2025 | -32.25 Mn |
| Jun 30, 2025 | -34.07 Mn |
| Mar 31, 2025 | -37.70 Mn |
| Dec 31, 2024 | -51.90 Mn |
| Sep 30, 2024 | -47.68 Mn |
| Jun 30, 2024 | -38.43 Mn |
| Mar 31, 2024 | -48.00 Mn |
| Dec 31, 2023 | -44.12 Mn |
| Sep 30, 2023 | -45.17 Mn |
| Jun 30, 2023 | -52.76 Mn |
| Mar 31, 2023 | -18.88 Mn |
| Dec 31, 2022 | -54.96 Mn |
| Sep 30, 2022 | -83.56 Mn |
| Jun 30, 2022 | -76.11 Mn |
| Mar 31, 2022 | -65.69 Mn |
| Dec 31, 2021 | -69.45 Mn |
| Sep 30, 2021 | -43.30 Mn |
| Jun 30, 2021 | -55.13 Mn |